Court Bans German Health Fund Drugs List
Public-sector health funds in Germany may not publish any list ofpharmaceutical products containing controversial drugs or which positively recommend cheaper drugs as alternatives.
This is the ruling of the Dusseldorf state court on the 1997 Drug Prescription Report, the AVR, in a cost brought against seven health funds by the drugmaker Dr Willmar Schwabe Arzneimittel on the grounds of the commercial impact of this annual report. The court deals especially with commercial cases and is said to have judged that the published report amounts to a form of impermissible control of the drug market. An appeal may be made against the judgement to a higher court.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze